ASX
AUSTRALIAN SECURITIES EXCHANGE

MARKET RELEASE

4 October 2012

Mayne Pharma Group Limited

TRADING HALT

The securities of Mayne Pharma Group Limited (the "Company") will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State until the earlier of the commencement of trading on 8 October 2012 or when the announcement is released to the market.

Security Code: MYX

Dean Litis
Principal Adviser, Listings (Melbourne)

Manager, Company Announcements
ASX Limited
Rialto Towers
Level 45, 525 Collins Street
MELBOURNE VIC 3000

4 October 2012

Via E-Lodgement

Dear Sir/Madam

Mayne Pharma Group Limited – Request for Trading Halt

Mayne Pharma Group Limited ACN 115 832 963 (ASX: MYX) (**Mayne Pharma**) requests a trading halt from the commencement of trading on 4 October 2012 as the company is considering a significant transaction and will make a further announcement when a decision has been made.

For the purposes of ASX Listing Rule 17.1, Mayne Pharma provides the following further information:

(a) Mayne Pharma expects that the trading halt will remain in place until the commencement of trading on 8 October 2012, unless, before that time, Mayne Pharma makes the announcement or requests that the trading halt be lifted; and

(b) Mayne Pharma is not aware of any reason why the trading halt should not be granted.

If you have any queries, please do not hesitate to contact the writer.

Yours Sincerely,
Mayne Pharma Group Limited

Mark Cansdale
Chief Financial Officer and Company Secretary